aminogluthemide (Cytadren)

Introduction

Tradename: Cytadren.

Indications

• suppression of adrenal function in selected patients with Cushing's syndrome
• postmenopausal women with advanced breast carcinoma
• patients with metastatic prostate cancer

Dosage

• start: 250 mg PO every 6 hours
• increase up to 2 g/day divided BID-TID (to decrease incidence of nausea/vomiting)

Tabs: 250 mg

Adverse effects

• common (> 10%)
  • headache, dizziness, drowsiness & lethargy, ataxia, lupus-like syndrome, rash, nausea/vomiting, anorexia, cholestatic jaundice, myalgia, nephrotoxicity, pulmonary alveolardamage
• less common (1-10%)
  • orthostatic hypotension, tachycardia, hirsutism, adrenocortical insufficiency
• rare
  • neutropenia, leukopenia, thrombocytopenia, pancytopenia, agranulocytosis

* most adverse effects diminish in incidence & severity after 2-6 weeks of therapy

Drug interactions

• aminophylline
• corticosteroids
• theophylline
• warfarin

More general terms

• miscellaneous pharmacologic agent

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=2145
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=86473
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=199477
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=86488